Affimed N.V. (0HL9.L)
USD 0.98
(-10.93%)
USD 0.98
(-10.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -19.17 Million EUR | 88.86% |
| 2022 | -172.09 Million EUR | 3.82% |
| 2021 | -178.93 Million EUR | -22.93% |
| 2020 | -145.55 Million EUR | -58.13% |
| 2019 | -92.04 Million EUR | -2.21% |
| 2018 | -90.05 Million EUR | -175.67% |
| 2017 | -32.66 Million EUR | -6.01% |
| 2016 | -30.81 Million EUR | 57.3% |
| 2015 | -72.16 Million EUR | -101.41% |
| 2014 | -35.83 Million EUR | -5620.8% |
| 2013 | 649 Thousand EUR | -99.05% |
| 2012 | 68.59 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 3.75 Million EUR | 117.7% |
| 2024 Q1 | 1.72 Million EUR | 108.98% |
| 2023 Q3 | -41.74 Million EUR | 60.17% |
| 2023 Q4 | -19.17 Million EUR | 54.05% |
| 2023 FY | -19.17 Million EUR | 88.86% |
| 2023 Q1 | -139.12 Million EUR | 19.16% |
| 2023 Q2 | -104.81 Million EUR | 24.67% |
| 2022 FY | -172.09 Million EUR | 3.82% |
| 2022 Q1 | -151.21 Million EUR | 15.49% |
| 2022 Q3 | -204.16 Million EUR | 6.53% |
| 2022 Q4 | -172.09 Million EUR | 15.71% |
| 2022 Q2 | -218.43 Million EUR | -44.45% |
| 2021 Q1 | -229.36 Million EUR | -57.58% |
| 2021 FY | -178.93 Million EUR | -22.93% |
| 2021 Q4 | -178.93 Million EUR | 4.61% |
| 2021 Q3 | -187.59 Million EUR | 11.27% |
| 2021 Q2 | -211.43 Million EUR | 7.82% |
| 2020 Q2 | -82.76 Million EUR | -2.9% |
| 2020 FY | -145.55 Million EUR | -58.13% |
| 2020 Q1 | -80.43 Million EUR | 12.62% |
| 2020 Q4 | -145.55 Million EUR | -66.79% |
| 2020 Q3 | -87.26 Million EUR | -5.44% |
| 2019 Q3 | -56.2 Million EUR | 5.52% |
| 2019 Q2 | -59.48 Million EUR | -1.84% |
| 2019 Q1 | -58.41 Million EUR | 35.14% |
| 2019 FY | -92.04 Million EUR | -2.21% |
| 2019 Q4 | -92.04 Million EUR | -63.77% |
| 2018 Q3 | -31.74 Million EUR | 23.42% |
| 2018 Q2 | -41.46 Million EUR | 15.0% |
| 2018 Q1 | -48.77 Million EUR | -49.3% |
| 2018 FY | -90.05 Million EUR | -175.67% |
| 2018 Q4 | -90.05 Million EUR | -183.65% |
| 2017 Q3 | -26.16 Million EUR | 30.15% |
| 2017 Q4 | -32.66 Million EUR | -24.87% |
| 2017 FY | -32.66 Million EUR | -6.01% |
| 2017 Q2 | -37.45 Million EUR | 15.49% |
| 2017 Q1 | -44.31 Million EUR | -43.81% |
| 2016 FY | -30.81 Million EUR | 57.3% |
| 2016 Q3 | -32.04 Million EUR | 11.77% |
| 2016 Q2 | -36.32 Million EUR | 18.83% |
| 2016 Q1 | -44.75 Million EUR | 37.99% |
| 2016 Q4 | -30.81 Million EUR | 3.84% |
| 2015 FY | -72.16 Million EUR | -101.41% |
| 2015 Q3 | -56.05 Million EUR | 9.57% |
| 2015 Q2 | -61.98 Million EUR | -90.57% |
| 2015 Q1 | -32.52 Million EUR | 9.22% |
| 2015 Q4 | -72.16 Million EUR | -28.74% |
| 2014 Q1 | -68 Thousand EUR | -110.48% |
| 2014 Q3 | -41.74 Million EUR | -1345.0% |
| 2014 Q4 | -35.83 Million EUR | 14.17% |
| 2014 Q2 | 3.35 Million EUR | 5030.88% |
| 2014 FY | -35.83 Million EUR | -5620.8% |
| 2013 Q4 | 649 Thousand EUR | 0.0% |
| 2013 FY | 649 Thousand EUR | -99.05% |
| 2012 FY | 68.59 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 77.986% |
| Dynavax Technologies Corporation | 106.63 Million USD | 117.985% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -112.711% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.233% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 42.798% |
| Perrigo Company plc | 3.32 Billion USD | 100.577% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 160.147% |
| Illumina, Inc. | 1.21 Billion USD | 101.58% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.071% |
| Nektar Therapeutics | 210.24 Million USD | 109.122% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 83.161% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.149% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 113.219% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 366.843% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 105.064% |
| Waters Corporation | 1.96 Billion USD | 100.978% |
| Biogen Inc. | 6.28 Billion USD | 100.305% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -170.113% |
| Adicet Bio, Inc. | -142 Million USD | 86.495% |
| Evolus, Inc. | 63.7 Million USD | 130.103% |
| bluebird bio, Inc. | 108.57 Million USD | 117.664% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 47.892% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 104.181% |
| FibroGen, Inc. | 56.76 Million USD | 133.784% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 101.675% |
| Homology Medicines, Inc. | 18.43 Million USD | 204.019% |
| Geron Corporation | 14.76 Million USD | 229.923% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 101.21% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 375.227% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 109.683% |
| Myriad Genetics, Inc. | 88.1 Million USD | 121.768% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 29.232% |
| OPKO Health, Inc. | 230.68 Million USD | 108.314% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 64.653% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 82.785% |
| Zoetis Inc. | 4.76 Billion USD | 100.403% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -90.428% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 100.914% |
| Exelixis, Inc. | -73.05 Million USD | 73.747% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.799% |
| uniQure N.V. | -102.95 Million USD | 81.372% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -31.609% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 87.301% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 90.402% |
| Verastem, Inc. | -37.27 Million USD | 48.554% |
| Imunon, Inc. | -4.69 Million USD | -308.106% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 101.819% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 101.98% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 110.817% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 85.836% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 101.389% |
| TG Therapeutics, Inc. | 17.86 Million USD | 207.368% |
| Blueprint Medicines Corporation | 702.83 Million USD | 102.729% |
| Insmed Incorporated | 721.62 Million USD | 102.658% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 38.566% |
| Incyte Corporation | -3.17 Billion USD | 99.396% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 102.504% |